Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Sorrento Announces Drilling Contract & Receives Permit to Drill Bottom Brook Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Trevena Inc (EM) TRVN

Healthcare Biotechnology
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.


EXPM:TRVN - Post by User

Trevena Inc (EM)
Bullboard Posts
Next >>
User Avatar Image
(13)
•••
  • SandMan67X
Post by SandMan67on Aug 06, 2020 1:57pm
173 Views
Post# 31374238

FDA - Oliceridine

FDA - OliceridineOne more day and we find out if the FDA has approved their resubmission on their morphine alternative drug.  https://www.globenewswire.com/news-release/2020/03/05/1995745/0/en/Trevena-Announces-FDA-Has-Set-PDUFA-Date-of-August-7-2020-for-Oliceridine.html

Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities